Clinical trials: Differentiated Thyroid Cancer, active
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Radioiodine Refractory Differentiated Thyroid Cancer
Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer
177Lu-LNC1004 Injection, a radiopharmaceutical targeting FAP, has demonstrated preliminary antitumor effect in advanced FAP-positive solid tumor patients.
- Trial name
- NCT06898437
- Testing
- 177Lu-LNC1004 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Microcarcinoma
Decision Aid Efficacy in Low Risk Thyroid Cancer
Low-risk thyroid cancer grows very slowly. More than 99% of patients with this cancer survive for at least 5 years. There are 3 main treatment options: remove the whole thyroid, remove just the part of the thyroid with the cancer…
- Conditions
- Differentiated Thyroid Cancer (DTC), Papillary Thyroid Microcarcinoma, Papillary Thyroid Carcinoma
- Trial name
- NCT07536412
- Testing
- Decision Aid
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Maryland, Baltimore
Radioiodine-refractory Differentiated Thyroid Cancer
A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients
This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R…
- Trial name
- NCT07770074
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma
Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
This study measures circulating immune-signaling molecules before thyroid surgery to determine whether they differ between patients whose thyroid nodule proves to be a differentiated thyroid carcinoma and patients whose nodule…
- Conditions
- Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma, Thyroid Cancer, Thyroid Nodule
- Trial name
- THINC (NCT07907432)
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- Marmara University
Differentiated Thyroid Cancer, Thyroid Cancer
Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy
This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.
- Conditions
- Differentiated Thyroid Cancer, Thyroid Cancer, Levothyroxine, Liothyronine
- Trial name
- THRIVE (NCT06647602)
- Testing
- Euthyrox (levothyroxine), Cytomel (liothyronine)
- Where
- 2 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- University Medical Center Groningen
Thyroid Neoplasms
Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
The study aims to observe and investigate the efficacy and safety of Anlotinib capsules in patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma in the real world, and to summarize…
- Trial name
- NCT05994365
- Testing
- Anlotinib Hydrochloride Capsule
- Where
- 3 sites in China
- Volunteers
- 380 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Thyroid Cancer, Thyroid Neoplasms
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
IoN is a phase II/III trial that will look to ascertain whether or not radio-iodine ablation is necessary for low risk differentiated thyroid cancer patients.
- Trial name
- IoN (NCT01398085)
- Testing
- I131 1.1 GBq, No Radioactive iodine (No-RAI) ablation
- Where
- 36 sites in United Kingdom
- Volunteers
- 504 people
- Sponsor
- University College, London
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Refractory Differentiated Thyroid Gland Carcinoma
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which…
- Trial name
- NCT06475989
- Testing
- Biospecimen Collection, Cabozantinib, Computed Tomography
- Where
- 307 sites in United States
- Volunteers
- 264 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Papillary Thyroid Cancer, Pediatric Cancer
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females.
- Conditions
- Papillary Thyroid Cancer, Pediatric Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT05024929
- Testing
- Whole body scan
- Where
- 9 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Children's Hospital of Philadelphia
Differentiated Thyroid Cancer (DTC)
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the…
- Trial name
- NCT04940052
- Testing
- Dabrafenib, Trametinib
- Where
- 41 sites in United States, Argentina and 9 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation, Advanced PDTC or ATC With NRAS Mutation
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
This phase II trial evaluates Tunlametinib (MEK inhibitor) ± PD-1 in NRAS-mutant advanced thyroid cancer. Key Objectives: Assess efficacy (ORR by RECIST v1.1) Evaluate safety profiles Study Design: Single-arm, single-center 4…
- Trial name
- NCT06970353
- Testing
- Tunlametinib, Tunlametinib+PD-1 mAb
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
This pilot clinical trial is intended to compare the effect of a psychosocial support tool for young adult (YA)cancer survivors - including high-quality information about their cancer combined with evidence-based psychosocial…
- Conditions
- Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm, Melanoma, Thyroid Gland Follicular Carcinoma
- Trial name
- NCT07529080
- Testing
- Internet-Based Intervention, Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- University of Michigan Rogel Cancer Center
Thyroid Carcinoma
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
This is a non-interventional, multi center post-authorization safety study that includes all patients diagnosed as Unresectable Differentiated Thyroid Carcinoma (DTC) and treated with Sorafenib within a certain period.
- Trial name
- JPMS-DTC (NCT02185560)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 453 people
- Sponsor
- Bayer
Genomics, Thyroid Cancer
Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk Stratification and Post-Treatment Surveillance in Fresh Thyroid Cancer Patients
Thyroid cancer is the most common endocrine malignancy, and although differentiated thyroid cancer (DTC) generally confers favorable outcomes, 10-20% of patients still face substantial postoperative risks, including local…
- Conditions
- Genomics, Thyroid Cancer, NGS
- Trial name
- NCT07532356
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Differentiated Thyroid Cancer
Primary Care Transfer for Thyroid Cancer Patients
Introduction: Differentiated thyroid cancer (DTC) is the most common endocrine malignancy. It presents low recurrence rates (2-5%) and the consensus of DTC recommends long-term follow-up, without a definition of maximum follow-up…
- Trial name
- NCT03794375
- Testing
- Telehealth, Usual care
- Where
- Brazil
- Volunteers
- 206 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Differentiated Thyroid Cancer
Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy
Radiofrequency (RF) could be technically feasible and effective in the treatment of lymph node metastases of differentiated thyroid cancer.
- Trial name
- METATHYRAF (NCT03416686)
- Testing
- Radiofrequency (RF star electrode electrode_Fixed)
- Where
- 3 sites in France
- Volunteers
- 14 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Thyroid Cancer, Cancer of the Thyroid
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).
- Trial name
- NCT07092514
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Washington University School of Medicine
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis